Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 2394Neoplasms 1813Carcinoma, Non-Small-Cell Lung 1596Prostatic Neoplasms 1296Colorectal Neoplasms 1138Lung Neoplasms 981Neoplasm Metastasis 830Multiple Myeloma 791Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 661Melanoma 659Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 566Recurrence 562Brain Neoplasms 526Glioblastoma 512Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 464Lymphoma 453Uterine Cervical Neoplasms 449Carcinoma, Renal Cell 423Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 388Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 351

Interventions

pembrolizumab 1Tadalafil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pyridoxine-dependent epilepsy × 1 year × Clear all
NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

Phase 2 Completed
7 enrolled 14 charts
GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡